Cargando…
Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
Aneuploidy is the hallmark of malignancy. Our previous study successfully detected nonhematogenic circulating aneuploidy cells (CACs) in types of gliomas. The current prospective clinical study aims to further precisely subcategorize aneuploid CACs, including CD31(−) circulating tumor cells (CTCs) a...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530864/ https://www.ncbi.nlm.nih.gov/pubmed/35940591 http://dx.doi.org/10.1111/cas.15516 |
_version_ | 1784801776125345792 |
---|---|
author | Li, Mingxiao Gao, Faliang Ren, Xiaohui Dong, Gehong Chen, Hongyan Lin, Alexander Y. Wang, Daisy Dandan Liu, Mingyang Lin, Peter Ping Shen, Shaoping Jiang, Haihui Yang, Chuanwei Zhang, Xiaokang Zhao, Xuzhe Zhu, Qinghui Li, Ming Cui, Yong Lin, Song |
author_facet | Li, Mingxiao Gao, Faliang Ren, Xiaohui Dong, Gehong Chen, Hongyan Lin, Alexander Y. Wang, Daisy Dandan Liu, Mingyang Lin, Peter Ping Shen, Shaoping Jiang, Haihui Yang, Chuanwei Zhang, Xiaokang Zhao, Xuzhe Zhu, Qinghui Li, Ming Cui, Yong Lin, Song |
author_sort | Li, Mingxiao |
collection | PubMed |
description | Aneuploidy is the hallmark of malignancy. Our previous study successfully detected nonhematogenic circulating aneuploidy cells (CACs) in types of gliomas. The current prospective clinical study aims to further precisely subcategorize aneuploid CACs, including CD31(−) circulating tumor cells (CTCs) and CD31(+) circulating tumor endothelial cells, and thoroughly investigate the clinical utilities of these different subtypes of cells. Co‐detection and analysis of CTCs and circulating tumor‐derived endothelial cells (CTECs) expressing CD133, glial fibrillary acidic protein (GFAP), or epidermal growth factor receptor variant III (EGFR vIII) were performed by integrated subtraction enrichment and immunostaining fluorescence in situ hybridization (SE‐iFISH) in 111 preoperative primary diffuse glioma patients. Aneuploid CACs could be detected in most de novo glioma patients. Among detected CACs, 45.6% were CD31(−)/CD45(−) aneuploid CTCs and the remaining 54.4% were CD31(+)/CD45(−) aneuploid CTECs. Positive detection of CTECs significantly correlated with disruption of the blood–brain barrier. The median number of large CTCs ((L)CTCs, >5 μm, 2) in low‐grade glioma (WHO grade 2) was less than high‐grade glioma (WHO grades 3 and 4) (3, p = 0.044), but this difference was not observed in small CTCs ((S)CTCs, ≤5 μm), CTECs or CACs (CTCs + CTECs). The numbers of CTCs, CTECs, or CACs in patients with contrast‐enhancing (CE) lesions considerably exceeded that of non‐CE lesions (p < 0.05). Receiver operating characteristic curves demonstrated that CD31(+) CTECs, especially (L)CTECs, exhibited a close positive relationship with CE lesions. Survival analysis revealed that the high number of CD31(−) CTCs could be an adverse factor for compromised progression‐free survival and overall survival. Longitudinal surveillance of CD31(−) CTCs was suitable for evaluating the therapeutic response and for monitoring potential emerging treatment resistance. |
format | Online Article Text |
id | pubmed-9530864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95308642022-10-11 Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas Li, Mingxiao Gao, Faliang Ren, Xiaohui Dong, Gehong Chen, Hongyan Lin, Alexander Y. Wang, Daisy Dandan Liu, Mingyang Lin, Peter Ping Shen, Shaoping Jiang, Haihui Yang, Chuanwei Zhang, Xiaokang Zhao, Xuzhe Zhu, Qinghui Li, Ming Cui, Yong Lin, Song Cancer Sci Original Articles Aneuploidy is the hallmark of malignancy. Our previous study successfully detected nonhematogenic circulating aneuploidy cells (CACs) in types of gliomas. The current prospective clinical study aims to further precisely subcategorize aneuploid CACs, including CD31(−) circulating tumor cells (CTCs) and CD31(+) circulating tumor endothelial cells, and thoroughly investigate the clinical utilities of these different subtypes of cells. Co‐detection and analysis of CTCs and circulating tumor‐derived endothelial cells (CTECs) expressing CD133, glial fibrillary acidic protein (GFAP), or epidermal growth factor receptor variant III (EGFR vIII) were performed by integrated subtraction enrichment and immunostaining fluorescence in situ hybridization (SE‐iFISH) in 111 preoperative primary diffuse glioma patients. Aneuploid CACs could be detected in most de novo glioma patients. Among detected CACs, 45.6% were CD31(−)/CD45(−) aneuploid CTCs and the remaining 54.4% were CD31(+)/CD45(−) aneuploid CTECs. Positive detection of CTECs significantly correlated with disruption of the blood–brain barrier. The median number of large CTCs ((L)CTCs, >5 μm, 2) in low‐grade glioma (WHO grade 2) was less than high‐grade glioma (WHO grades 3 and 4) (3, p = 0.044), but this difference was not observed in small CTCs ((S)CTCs, ≤5 μm), CTECs or CACs (CTCs + CTECs). The numbers of CTCs, CTECs, or CACs in patients with contrast‐enhancing (CE) lesions considerably exceeded that of non‐CE lesions (p < 0.05). Receiver operating characteristic curves demonstrated that CD31(+) CTECs, especially (L)CTECs, exhibited a close positive relationship with CE lesions. Survival analysis revealed that the high number of CD31(−) CTCs could be an adverse factor for compromised progression‐free survival and overall survival. Longitudinal surveillance of CD31(−) CTCs was suitable for evaluating the therapeutic response and for monitoring potential emerging treatment resistance. John Wiley and Sons Inc. 2022-08-08 2022-10 /pmc/articles/PMC9530864/ /pubmed/35940591 http://dx.doi.org/10.1111/cas.15516 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Li, Mingxiao Gao, Faliang Ren, Xiaohui Dong, Gehong Chen, Hongyan Lin, Alexander Y. Wang, Daisy Dandan Liu, Mingyang Lin, Peter Ping Shen, Shaoping Jiang, Haihui Yang, Chuanwei Zhang, Xiaokang Zhao, Xuzhe Zhu, Qinghui Li, Ming Cui, Yong Lin, Song Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas |
title | Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas |
title_full | Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas |
title_fullStr | Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas |
title_full_unstemmed | Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas |
title_short | Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas |
title_sort | nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530864/ https://www.ncbi.nlm.nih.gov/pubmed/35940591 http://dx.doi.org/10.1111/cas.15516 |
work_keys_str_mv | AT limingxiao nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT gaofaliang nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT renxiaohui nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT donggehong nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT chenhongyan nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT linalexandery nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT wangdaisydandan nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT liumingyang nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT linpeterping nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT shenshaoping nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT jianghaihui nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT yangchuanwei nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT zhangxiaokang nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT zhaoxuzhe nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT zhuqinghui nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT liming nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT cuiyong nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas AT linsong nonhematogeniccirculatinganeuploidcellsconferinferiorprognosisandtherapeuticresistanceingliomas |